Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4535591 | 1.00 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPK1SMN1; SMN2F10 | |
| SCHEMBL4525233 | 0.86 | F10 (0.36) | F10 | |
| SCHEMBL4528541 | 0.86 | F10 (0.37) | F10 | |
| SCHEMBL4528535 | 0.86 | F10 (0.37) | F10 | |
| SCHEMBL6080076 | 0.84 | F10 (0.51) | F10CYP3A4CYP2D6TSHR | |
| SCHEMBL4526469 | 0.82 | F10 (0.37) | ALDH1A1LMNAMAPK1SMN1; SMN2F10 | |
| SCHEMBL4526473 | 0.82 | F10 (0.37) | ALDH1A1LMNAMAPK1SMN1; SMN2F10 | |
| SCHEMBL4532259 | 0.77 | F10 (0.46) | F10 | |
| SCHEMBL4532216 | 0.77 | CYP2D6 (0.45) | ALDH1A1LMNAMAPK1SMN1; SMN2CYP3A4 | |
| SCHEMBL4522105 | 0.74 | F10 (0.46) | ALDH1A1LMNAMAPK1F10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1864984-A1 | TRICYCLIC SPIRO COMPOUND COMPRISING ACYL GROUP BOUND TO NITROGEN ATOM IN THE RING | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | KCNH1, SCN1A, SCN10A | ALDH1A1 2791/4885LMNA 870/4885MAPK1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.